Tarsus Pharmaceuticals adquire Alkeus Pharmaceuticals (TARS:NASDAQ)
· seekingalpha.com
Tarsus (TARS) adquire a Alkeus por US$ 450 milhões à vista mais marcos regulatórios, adicionando o gildeuretinol, medicamento para a doença de Stargardt, ao seu portfólio.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...